Literature DB >> 12399057

Analysis of hepatic resection of metastasis originating from gastric adenocarcinoma.

Johannes Zacherl1, Maximilian Zacherl, Christian Scheuba, Rudolf Steininger, Etienne Wenzl, Ferdinand Mühlbacher, Raimund Jakesz, Friedrich Längle.   

Abstract

Few patients with metastatic gastric cancer have disease that is amenable to curative surgery. Thus far, little is known about liver surgery for metastases arising from gastric adenocarcinoma and prognostic factors. Of 73 patients operated on between 1980 and 1999 for noncolorectal, non-neuroendocrine hepatic metastases, 15 underwent liver resection for gastric adenocarcinoma metastasis. Ten patients underwent synchronous hepatic resection and five underwent metachronous hepatic surgery after a median disease-free interval of 10 months (range 6.1 to 47.3 months). None of the patients died within the first 30 days after surgery, and the in-hospital mortality rate was 6.7%. Among patients in the synchronous group, 26.7% experienced major complications mainly associated with gastric surgery. Overall median survival was 8.8 months (range 4 to 51 months); two patients survived more than 3 years. Univariate analysis revealed that the appearance of liver metastasis (synchronous vs. metachronous), the distribution of liver metastases (unilobar vs. bilobar), and the primary tumor site (proximal vs. distal) were marginally significant predictive factors regarding overall survival. Because of its high morbidity, synchronous liver resection for metastases originating from gastric adenocarcinoma is rarely followed by survival longer than 2 years. Primary tumor localization within the proximal third of the stomach and bilobar liver involvement appear to be predictive of poor outcome. On the other hand, curative resection of metachronous liver metastases may allow long-term survival in selected patients. Copyright 2002 The Society for Surgery of the Alimentary Tract, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12399057     DOI: 10.1016/s1091-255x(01)00075-0

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  21 in total

1.  Intraoperative ultrasonography versus helical computed tomography and computed tomography with arterioportography in diagnosing colorectal liver metastases: lesion-by-lesion analysis.

Authors:  J Schmidt; M Strotzer; S Fraunhofer; H Boedeker; H Zirngibl
Journal:  World J Surg       Date:  2000-01       Impact factor: 3.352

2.  Management of gastric cancer patients with synchronous hepatic metastasis: a retrospective study.

Authors:  M Rafique; W Adachi; S Kajikawa; M Kobayashi; S Koike; T Kuroda
Journal:  Hepatogastroenterology       Date:  1995 Sep-Oct

3.  Hepatic resection for noncolorectal, nonneuroendocrine metastases: a fifteen-year experience with ninety-six patients.

Authors:  L E Harrison; M F Brennan; E Newman; J G Fortner; A Picardo; L H Blumgart; Y Fong
Journal:  Surgery       Date:  1997-06       Impact factor: 3.982

4.  [Liver resections of metastases of non-colorectal primary tumors].

Authors:  J K Seifert; T Junginger
Journal:  Chirurg       Date:  1996-02       Impact factor: 0.955

5.  Resection and embolization in the management of secondary hepatic tumors.

Authors:  L H Blumgart; D J Allison
Journal:  World J Surg       Date:  1982-01       Impact factor: 3.352

6.  Hepatic resection of liver metastases from gastric carcinoma.

Authors:  M Miyazaki; H Itoh; K Nakagawa; S Ambiru; H Shimizu; A Togawa; M Shiobara; M Ohtsuka; K Sasada; Y Shimizu; S Yoshioka; N Nakajima; T Suwa; F Kimura
Journal:  Am J Gastroenterol       Date:  1997-03       Impact factor: 10.864

7.  Synchronous, metachronous, and multiple hepatic resections of liver tumors originating from primary gastric tumors.

Authors:  S D Bines; G England; D J Deziel; T R Witt; A Doolas; D L Roseman
Journal:  Surgery       Date:  1993-10       Impact factor: 3.982

8.  Results of surgical resection of liver metastases from non-colorectal primaries.

Authors:  T Berney; G Mentha; A D Roth; P Morel
Journal:  Br J Surg       Date:  1998-10       Impact factor: 6.939

9.  [Liver resection of hematogenous and infiltrating metastases].

Authors:  J M Funovics; E Wenzl; R Függer; M Schemper
Journal:  Wien Klin Wochenschr       Date:  1986-12-19       Impact factor: 1.704

10.  Hepatic resection for metastatic tumours from gastric cancer: analysis of prognostic factors.

Authors:  T Ochiai; M Sasako; S Mizuno; T Kinoshita; T Takayama; T Kosuge; S Yamazaki; K Maruyama
Journal:  Br J Surg       Date:  1994-08       Impact factor: 6.939

View more
  46 in total

Review 1.  Liver resections in metastatic gastric cancer.

Authors:  Sid P Kerkar; Clinton D Kemp; Itzhak Avital
Journal:  HPB (Oxford)       Date:  2010-11       Impact factor: 3.647

Review 2.  Surgical resection of hepatic metastasis from gastric cancer: a review and new recommendation in the Japanese gastric cancer treatment guidelines.

Authors:  Yasuhiro Kodera; Kazumasa Fujitani; Norimasa Fukushima; Seiji Ito; Kei Muro; Norifumi Ohashi; Takaki Yoshikawa; Daisuke Kobayashi; Chie Tanaka; Michitaka Fujiwara
Journal:  Gastric Cancer       Date:  2014-04       Impact factor: 7.370

3.  Response to preoperative chemotherapy predicts survival in patients undergoing hepatectomy for liver metastases from gastric and esophageal cancer.

Authors:  Andreas Andreou; Luca Viganò; Giuseppe Zimmitti; Daniel Seehofer; Martin Dreyer; Andreas Pascher; Marcus Bahra; Wenzel Schoening; Volker Schmitz; Peter C Thuss-Patience; Timm Denecke; Gero Puhl; Jean-Nicolas Vauthey; Peter Neuhaus; Lorenzo Capussotti; Johann Pratschke; Sven-Christian Schmidt
Journal:  J Gastrointest Surg       Date:  2014-08-27       Impact factor: 3.452

4.  Reported outcome factors for hepatic metastasectomy.

Authors:  N Joseph Espat
Journal:  J Gastrointest Surg       Date:  2006-02       Impact factor: 3.452

5.  Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOG.

Authors:  Kozo Kataoka; Takahiro Kinoshita; Markus Moehler; Murielle Mauer; Kohei Shitara; Anna Dorothea Wagner; Stefanie Schrauwen; Takaki Yoshikawa; Franco Roviello; Masanori Tokunaga; Narikazu Boku; Michel Ducreux; Masanori Terashima; Florian Lordick
Journal:  Gastric Cancer       Date:  2017-02-01       Impact factor: 7.370

6.  Postoperative follow-up programs improve survival in curatively resected gastric and junctional cancer patients: a propensity score matched analysis.

Authors:  Leila Sisic; Moritz J Strowitzki; Susanne Blank; Henrik Nienhueser; Sara Dorr; Georg Martin Haag; Dirk Jäger; Katja Ott; Markus W Büchler; Alexis Ulrich; Thomas Schmidt
Journal:  Gastric Cancer       Date:  2017-07-24       Impact factor: 7.370

7.  Surgery for liver metastases originating from sarcoma-case series.

Authors:  Maximilian Zacherl; Gerwin A Bernhardt; Johannes Zacherl; Gerald Gruber; Peter Kornprat; Heinz Bacher; Hans-Jörg Mischinger; Reinhard Windhager; Raimund Jakesz; Thomas Grünberger
Journal:  Langenbecks Arch Surg       Date:  2011-07-08       Impact factor: 3.445

Review 8.  The role of surgery in the therapeutic approach of gastric cancer liver metastases.

Authors:  Aikaterini Mastoraki; Christina Benetou; Sotiria Mastoraki; Ioannis S Papanikolaou; Nikolaos Danias; Vassilios Smyrniotis; Nikolaos Arkadopoulos
Journal:  Indian J Gastroenterol       Date:  2016-08-16

9.  Liver resection for non-colorectal, non-neuroendocrine metastases: analysis of a multicenter study from Argentina.

Authors:  J Lendoire; M Moro; O Andriani; J Grondona; O Gil; G Raffin; J Silva; R Bracco; G Podestá; C Valenzuela; O Imventarza; J Pekolj; E De Santibañes
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

10.  The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone.

Authors:  Sid P Kerkar; Clinton D Kemp; Austin Duffy; Udai S Kammula; David S Schrump; King F Kwong; Martha Quezado; Barry R Goldspiel; Aradhana Venkatesan; Ann Berger; Melissa Walker; Mary Ann Toomey; Seth M Steinberg; Guiseppe Giaccone; Steven A Rosenberg; Itzhak Avital
Journal:  Trials       Date:  2009-12-23       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.